As policy ecosystem threatens biotech, new treatments could drop by over 50% in 20 years

For decades, the United States has led the world in developing new medicines, turning scientific breakthroughs into treatments that save and improve lives. But a new analysis suggests that leadership is at risk.

A new report from Magnolia Market Access finds that a combination of policy changes—a lack of research funding, regulatory staffing uncertainty, drug pricing proposals, and others—could significantly slow the pace of innovation, ultimately reducing the number of new treatments coming to market by up to 55% over the next two decades.

What’s changing?

The U.S. biopharmaceutical ecosystem depends on a delicate balance: early-stage research funding, a predictable regulatory process, and incentives that support high-risk investment. The report finds that all three parts of that system are facing enormous pressure.

Research funding is becoming less stable

Federal support, particularly through the National Institutes of Health (NIH), plays a critical role in early discovery. But recent funding disruptions and declines in grant opportunities are already slowing the flow of new ideas and scientific breakthroughs.

Regulatory capacity is strained

The U.S. Food and Drug Administration (FDA) is facing staffing losses and reduced institutional expertise, which will make the drug and treatment approval process less predictable and increase risk for developers.

Pricing policies are reshaping investment decisions

Changes introduced by the Inflation Reduction Act (IRA), along with international reference pricing proposals such as Most Favored Nation (MFN), are shortening the window for companies to recoup research investments, potentially discouraging work on complex or high-risk therapies.

Why does this matter for innovation?

Individually, these changes each have a significant impact. But their combined effect could be far greater than the sum of their parts.

When research funding is uncertain, early discoveries that fuel new breakthroughs decline. When the regulatory process is less predictable, fewer therapies advance. When financial incentives weaken, investment shifts away from drug development. Together, these dynamics reinforce one another, creating a cycle that slows innovation throughout the entire pipeline.

Magnolia’s modeling suggests that these pressures could lead to a significant reduction in new treatments over the next 20 years, potentially up to 55% fewer medicines than expected under current trends.

What’s at stake for patients?

At its core, this is not just a policy or economic issue; it is a patient issue.

Fewer new medicines mean fewer treatment options for people facing serious or life-threatening conditions. The impact could be especially acute for patients with rare diseases, cancer, and other conditions where scientific progress is still emerging and options are limited.

The effects may also take years to fully appear. Drug development often spans a decade or more, meaning today’s policy decisions will shape the treatments available to patients for a generation.

At the same time, there are broader implications. The United States has long been a global leader in biomedical innovation, attracting talent, investment, and research. But as uncertainty grows, companies may shift research and development to other countries like China, potentially weakening the U.S.’s position as a biotech leader and slowing access to new therapies domestically.

A call for a more coordinated approach

The report emphasizes that no single policy is driving these risks. Rather, it is the interaction of multiple changes across the ecosystem.

That means solutions will also need to be coordinated, ensuring stable research funding, predictable and efficient regulatory processes, and a policy environment that continues to incentivize innovation, particularly in areas of high unmet need.

The stakes are high: a future in which the U.S leads the world in biotech innovation and brings new treatments to patients will depend on the choices we make today.

The post As policy ecosystem threatens biotech, new treatments could drop by over 50% in 20 years appeared first on Bio.News.